Quality assurance (QA) in global health logistics goes well beyond regulatory compliance to serve as an active partner in safeguarding patient care. Through cross-functional collaboration, rigorous evaluation, and parallel risk mitigation, this case study illustrates how a critical supply chain challenge involving pediatric medication was successfully resolved.
The challenge: dual priorities in a complex scenario
Upon receipt of an in-country shipment of essential pediatric medication (pediatric azithromycin oral suspension), a unit deviation was identified: one box was missing all 48 bottles of medicine, leaving only the measuring cap bag. With local stock levels constrained, this shortage created a potential stockout risk that directly threatened treatment continuity for pediatric patients. To address this challenge effectively, two critical objectives had to be balanced simultaneously:
- Root cause analysis:
Conducting a thorough quality investigation to understand where the deviation occurred. - Treatment continuity:
Ensuring uninterrupted access to essential care for pediatric patients.
Collaborative investigation and continuous improvement
Led by the PFSCM QA team, an integrated investigation was initiated in close partnership with the recipient, logistics providers, the manufacturing partner, internal supply chain teams, and program stakeholders.
PFSCM QA critically reviewed the initial root cause analyses and corrective and preventive action (CAPA) plans submitted by both the manufacturer and the third-party logistics provider (3PL), and requested further investigation to ensure the findings were adequately supported. Through close collaboration and a detailed review of shipment records and supporting documentation, the teams strengthened the root cause assessments and proposed corrective and preventive actions.
Through this joint initiative, key insights were gained that prompted the manufacturer to strengthen packaging safeguards, while receiving facilities established upgraded intake procedures, including photographic verification before package opening.
Parallel action to protect patients
In standard operational scenarios, replacement decisions and corrective actions often follow the completion of a full investigation and root cause assessment. However, recognizing that thorough technical reviews take time and that urgent patient needs cannot wait, the team utilized a dual-track approach based on immediate risk. A replacement shipment was initiated in parallel with the ongoing technical review, successfully preventing a stockout and protecting treatment continuity while long-term preventive measures were finalized.
Key takeaways
- Risk mitigation and investigation can proceed in parallel:
In critical situations, technical investigations and operational risk mitigation should proceed simultaneously. - Collaboration turns deviations into improvement:
Joint engagement among QA, manufacturers, logistics partners, and program teams can strengthen controls across the supply chain. - Focus on patient safety:
Ultimately, this case highlights how quality assurance delivers strategic value far beyond regulatory adherence. By questioning preliminary findings, reinforcing preventive actions, and managing supply vulnerabilities concurrently, PFSCM turned an operational deviation into an opportunity for continuous improvement with patient needs at the heart of every decision.
By Anastasia Pantzi
Quality Assurance and Regulatory Officer and Responsible Pharmacist
